

Documents Relied Upon

ANALYST REPORTS

- “Global BioPharmaceuticals: Game Changes in Multiple Sclerosis,” *Barclays*, March 7, 2014.
- “Global Biotechnology,” *Credit Suisse*, April 4, 2014.
- “Global Biotechnology and Pharmaceuticals – AAN 2014,” *Credit Suisse*, April 30, 2014.
- “Multiple Sclerosis: It’s a Revolution! (vs. Evolution),” *Credit Suisse*, December 12, 2013.
- “Spec Pharmaceuticals,” *Morgan Stanley*, March 3, 2014.
- “Teva,” *Morgan Stanley*, March 14, 2014.
- “Teva Pharmaceutical Industries Ltd. (TEVA),” *Citi*, February 2, 2014.
- “Teva Pharmaceutical Industries Ltd. (TEVA),” *Citi*, April 4, 2014.

DRUG LABELS

- Aubagio[®] label, October 17, 2014.
- Avonex[®] label, August 28, 2014.
- Betaseron[®] label, September 25, 2015.
- Copaxone[®] label, January 28, 2014.
- Extavia[®] label, August, 14, 2009.
- Gilenya[®] label, August 4, 2015.
- Glatopa[™] label, April 16, 2015.
- Lemtrada[®] label, November 14, 2014.
- Novantrone[®] label, March 23, 2012.
- Plegridy[®] label, August 15, 2014.
- Rebif[®] label, March 10, 2015.
- Tecfidera[®] label, December 3, 2014.
- Tysabri[®] label, May 12, 2015.

EXPERT REPORTS AND DEPOSITIONS

- Declaration of Edward J. Fox, M.D., Ph.D. in Support of Patent Owner Yeda’s Response to Institution of Inter Parties Review filed on November 20, 2015.
- Deposition of Dr. Ari Green, October 22, 2015.

IMS DATA

- IMS Data.

INTERNAL DOCUMENTS

- 2015 MS Mid-Year Tracker, FINAL REPORT APPENDIX – SEPTEMBER 2015.
- TEVCOP00449084–115.
- TEVCOP00450191–93.
- TEVCOP00451650–52.

OTHER PUBLICATIONS

- Berndt, E. R., et al., “An Analysis of the Diffusion of New Antidepressants: Variety, Quality, and Marketing Efforts,” *The Journal of Mental Health Policy and Economics*, 2002, Vol. 5, No. 1, pp. 3–19.
- Cohen, J., et al., “Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial,” *JAMA Neurology*, October 12, 2015.
- Donohue, J. M., et al., “A Decade of Direct-to-Consumer Advertising of Prescription Drugs,” *The New England Journal of Medicine*, 2007, Vol. 357, No. 7, pp. 573–681.
- Leffler, K. B., “Persuasion or Information? The Economics of Prescription Drug Advertising,” *J.L. & Econ.*, 1981, Vol. 24, No. 1, pp. 45–74.
- Thomas, J. R., “Patent Infringement and Experimental Use Under the Hatch-Waxman Act: Current Issues,” *Congressional Research Service*, 2012.
- Venkataraman, S. and Stremersch, S., “The Debate on Influencing Doctors’ Decisions: Are Drug Characteristics the Missing Link?” *Management Science*, 2007, Vol. 53, No. 11, pp. 1688–1701.
- Wynn D., et al., “Patient Experience with Glatiramer Acetate 40 mg/1 mL Three-Times Weekly Treatment for Relapsing-Remitting Multiple Sclerosis: Results from the GLACIER Extension Study,” *The American Academy of Neurology 2015 Annual Meeting*, Washington, D.C., April 18–25, 2015.

PATENTS

- U.S. Patent No. 8,232,250.
- U.S. Patent No. 8,377,885.
- U.S. Patent No. 8,399,413.
- U.S. Patent No. 8,796,226.
- U.S. Patent No. 8,969,302.

WEBSITES

- Biogen, “Above MS™ Program,” available at <http://www.tecfidera.com/join-biogen-support/> (last visited on 11/12/2015).
- California State Board of Pharmacy, “2015 Lawbook for Pharmacy,” available at http://www.pharmacy.ca.gov/laws_regs/lawbook.pdf (last visited on 11/16/2015).
- Copaxone® website, available at www.copaxone.com (last visited on 11/12/2015).
- Copaxone® website, “3-TIMES-A-WEEK COPAXONE® 40 MG,” available at www.copaxone.com/about-copaxone/copaxone-40-mg (last visited on 11/12/2015).

- Copaxone[®] website, “COPAXONE[®] – A proven mix of efficacy, safety, and tolerability in relapsing forms of MS,” available at <https://www.copaxonehcp.com/about-copaxone> (last visited on 11/18/2015).
- IMS Health, “Our Company,” available at <http://www.imshealth.com/en/about-us/our-company> (last visited on 11/16/2015).
- National Multiple Sclerosis Society, “Definition of MS,” available at <http://www.nationalmssociety.org/What-is-MS/Definition-of-MS> (last visited on 11/12/2015).
- National Multiple Sclerosis Society, “MS Symptoms,” available at <http://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms> (last visited on 11/12/2015).
- National Multiple Sclerosis Society, “The MS Disease-Modifying Medications,” January 2015, available at <http://www.nationalmssociety.org/dmd> (last visited on 11/12/2015).
- National Multiple Sclerosis Society, “Types of MS,” available at <http://www.nationalmssociety.org/What-is-MS/Types-of-MS> (last visited on 11/12/2015).
- National Multiple Sclerosis Society, “What Is MS?” available at <http://www.nationalmssociety.org/What-is-MS> (last visited on 11/12/2015).
- Sandoz, “GlatopaCare[™],” available at http://glatopa.com/glatopa_care/index.shtml (last visited on 11/12/2015).
- Sandoz, “GlatopaCare[™]: Co-Pay Program & Insurance and Benefits Investigation,” available at http://www.glatopa.com/glatopa_care/financial_support.shtml (last visited on 11/12/2015).
- Teva, “Doctor Discussion Guide,” available at <https://www.copaxone.com/Resources/pdfs/DoctorDiscussionGuide.pdf> (last visited on 11/12/2015).
- Teva, “Informed Treatment Decision Brochure,” available at https://www.copaxone.com/Resources/pdfs/Informed_Treatment_Decision_Brochure.pdf (last visited on 11/12/2015).
- Teva, “Shared Solutions[®],” available at https://www.copaxone.com/Resources/pdfs/Shared_Solutions_Brochure.pdf (last visited on 11/12/2015).